AU1275095A - Antiviral composition of viral protein trans-dominant variants - Google Patents

Antiviral composition of viral protein trans-dominant variants

Info

Publication number
AU1275095A
AU1275095A AU12750/95A AU1275095A AU1275095A AU 1275095 A AU1275095 A AU 1275095A AU 12750/95 A AU12750/95 A AU 12750/95A AU 1275095 A AU1275095 A AU 1275095A AU 1275095 A AU1275095 A AU 1275095A
Authority
AU
Australia
Prior art keywords
viral protein
antiviral composition
variants
protein trans
dominant variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU12750/95A
Other versions
AU685560B2 (en
Inventor
Tania Guss
Majid Mehtali
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA filed Critical Transgene SA
Publication of AU1275095A publication Critical patent/AU1275095A/en
Application granted granted Critical
Publication of AU685560B2 publication Critical patent/AU685560B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Abstract

A composition resulting from a combination of trans-dominant variants of two viral proteins from a single virus, and the use thereof as a combination product are disclosed. A vector for expressing the two variants, a eukaryotic cell containing same, and a pharmaceutical composition for treating viral infections, are also disclosed.
AU12750/95A 1993-12-13 1994-12-13 Antiviral composition of viral protein trans-dominant variants Ceased AU685560B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9314914 1993-12-13
FR9314914A FR2713651B1 (en) 1993-12-13 1993-12-13 New composition for an antiviral effect.
PCT/FR1994/001457 WO1995016780A1 (en) 1993-12-13 1994-12-13 Antiviral composition of viral protein trans-dominant variants

Publications (2)

Publication Number Publication Date
AU1275095A true AU1275095A (en) 1995-07-03
AU685560B2 AU685560B2 (en) 1998-01-22

Family

ID=9453843

Family Applications (1)

Application Number Title Priority Date Filing Date
AU12750/95A Ceased AU685560B2 (en) 1993-12-13 1994-12-13 Antiviral composition of viral protein trans-dominant variants

Country Status (8)

Country Link
EP (1) EP0682708B9 (en)
AT (1) ATE277186T1 (en)
AU (1) AU685560B2 (en)
CA (1) CA2155844A1 (en)
DE (1) DE69434019T2 (en)
ES (1) ES2229232T3 (en)
FR (1) FR2713651B1 (en)
WO (1) WO1995016780A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458586B1 (en) 1998-11-02 2002-10-01 University Of Saskatchewan Bovine cells expressing adenovirus essential functions for propagation of recombinant adenoviral vectors
FR2982277B1 (en) 2011-11-08 2015-08-21 Agronomique Inst Nat Rech INDUCIBLE EXPRESSION CASSETTE AND USES THEREOF

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE207122T1 (en) * 1989-05-25 2001-11-15 Novartis Ag POLYVALENT REPRESSOR OF GENE FUNCTIONS

Also Published As

Publication number Publication date
CA2155844A1 (en) 1995-06-22
AU685560B2 (en) 1998-01-22
FR2713651B1 (en) 1996-04-19
EP0682708B1 (en) 2004-09-22
DE69434019T2 (en) 2005-09-15
ES2229232T3 (en) 2005-04-16
WO1995016780A1 (en) 1995-06-22
EP0682708B9 (en) 2005-03-02
EP0682708A1 (en) 1995-11-22
ATE277186T1 (en) 2004-10-15
DE69434019D1 (en) 2004-10-28
FR2713651A1 (en) 1995-06-16

Similar Documents

Publication Publication Date Title
IL110284A0 (en) Viral vectors and their use in gene therapy
EA199901031A1 (en) Derivatives of benzimidazole
AU681705B2 (en) Endosomolytically active particles
IL106600A0 (en) Peptides,pharmaceutical compositions containing the same and processes for the preparation thereof
AU6933496A (en) Antagonists of the oncogenic activity of the MDM2 protein and their use in the treatment of cancers
CA2011878A1 (en) Immunogenic regions on the e7 protein of human papillomavirus type 16
CA2130360A1 (en) Sulfonic Acid Derivatives in the Treatment of Viral Diseases
NZ237198A (en) Zymogen form of protein c, dna, vector and use as a pharmaceutical
AU2419595A (en) Recombinant human immunodeficiency virus vector and process for producing the same
CA2051288A1 (en) Viral targeted destruction of neoplastic cells
AU1463992A (en) Methods and pharmaceutical compositions for inhibiting protease from human immunodeficiency virus
AU5686196A (en) Use of an "immunodeficiency-virus suppressing lymphokine (ISL)" to inhibit the replication of viruses, in particular of retroviruses
AU4985596A (en) Novel aroylaniline derivatives, compositions and uses thereof in the treatment of viral infections
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease
HUP9802587A3 (en) Glucose-inducible recombinant viral vector, pharmaceutical composition containing it and cells transformed by this
AU6292694A (en) Novel polypeptide, dna coding for said polypeptide, recombinant vector containing said dna, recombinant virus prepared using said vector, and use thereof
AU3390995A (en) Novel implant and novel vector for the treatment of acquired diseases
AU1275095A (en) Antiviral composition of viral protein trans-dominant variants
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
MY114693A (en) Substituted benzenesulfonylureas and thioureas,processes for their preparation,their use for the production of pharmaceutical preparations, and pharmaceutical preparation containing them
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
MY115795A (en) Substituted benzenesulfonylureas and -thioureas, processes for their preparation and use of pharmaceutical preparations based on these compounds, and medicaments containing them
IL110585A0 (en) Tripeptides, their preparation and pharmaceutical compositions containing them
WO2000006735A8 (en) Interferon alpha hybrids
AU4756693A (en) 1-heteroarylazetidines and -pyrrolidines, process for their preparation and pharmaceutical compositions containing them